首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Stability behaviour of antiretroviral drugs and their combinations. 11: Characterization of interaction products of zidovudine and efavirenz, and evaluation of their anti HIV-1 activity, and physiochemical and ADMET properties
【24h】

Stability behaviour of antiretroviral drugs and their combinations. 11: Characterization of interaction products of zidovudine and efavirenz, and evaluation of their anti HIV-1 activity, and physiochemical and ADMET properties

机译:抗逆转录病毒药物及其组合的稳定性行为。 11:Zidovudine和Efaviraenz的相互作用产品的表征,评估其抗HIV-1活性,以及物理化学和冒名室的性质

获取原文
获取原文并翻译 | 示例
           

摘要

Zidovudine (ZDV) and efavirenz (EFV), which belong to two separate classes of antiretroviral drugs, viz., NRTI and NNRTI, respectively, were subjected to different stability test conditions alone and in solid mixtures to evaluate possibility of interaction among them. The exposed samples were analyzed by high performance liquid chromatography (HPLC) using a C18 column and a PDA detector. Two new peaks were observed in the sample in which 50 mu l CH3CN was added to increase the contact among the drugs, and which was subjected in open beaker to accelerated stability test condition of 40 degrees C/75%RH for 15 d. Subsequently, liquid chromatography-high resolution mass spectrometric (LC-HRMS) studies were carried out to obtain their accurate mass. The products were also isolated, and subjected to H-1, C-13, DEPT-135, COSY, HSQC and HMBC nuclear magnetic resonance (NMR) studies. The collective information allowed their structural characterization as isomeric cycloaddition products of the two drugs. As these were novel compounds, they were subjected to testing for cytotoxicity and in vitro anti-HIV-1 activity against primary isolates HIV-1(UG070) (X4, subtype D) and HIV-1(vB59) (R5, subtype C) in TZM-bl cell line. The two were found to show weak activity against the standard drugs. The reason was sought through molecular docking studies, which highlighted that it was perhaps their comparative bigger molecular size than the drugs of both classes used currently in HIV therapy. Being previously unknown molecules, their in silico physicochemical and ADMET properties were also evaluated using ADMET Predictor (TM) and TOPKAT software. (C) 2019 Elsevier B.V. All rights reserved.
机译:Zidovudine(ZDV)和EFAVIRENZ(EFV)属于两种单独的抗逆转录病毒药物,ZIZ,NRTI和NNRTI,单独进行不同的稳定性试验条件,并在固体混合物中进行不同的混合物,以评估它们之间相互作用的可能性。通过使用C18柱和PDA检测器通过高效液相色谱(HPLC)分析暴露的样品。在加入50μLCH3CN的样品中观察到两种新峰,以增加药物中的接触,并在开放式烧杯中进行,以加速40℃/ 75%RH的稳定性试验条件15天。随后,进行液相色谱 - 高分辨率质谱(LC-HRMS)研究以获得其精确的质量。还分离产物,并进行H-1,C-13,Dept-135,Cozy,HSQC和HMBC核磁共振(NMR)研究。集体信息允许其结构表征作为两种药物的异构环加成产品。由于这些是新化合物,对其进行细胞毒性和体外抗HIV-1对初级分离物的抗-HIV-1活性进行测试,则对初级分离物(UG070)(X4,亚型D)和HIV-1(VB59)(R5,亚型C)进行在TZM-BL细胞系中。发现这两者患有对标准药物的薄弱活动。原因是通过分子对接研究寻求的,这突出显示它可能比目前艾滋病毒治疗中的两类药物更大的分子大小。作为以前未知的分子,还使用呼气预测器(TM)和Topkat软件评估其在硅理物理化学和呼吸垫种中。 (c)2019 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号